EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieVergleichsstudieÄquivalenzstudieOpen Access · CC BY-NC 4.0

Safety and Efficacy of Reduced-Port Versus Conventional Laparoscopic Distal Gastrectomy for Early Gastric Cancer: A Multicenter, Randomized, Non-inferiority Trial (KLASS-12)

Hyoung-Il Kim iD, Hoseok Seo iD, Hoon Hur iD, Chang Min Lee iD, Sang-Hoon Ahn iD, Dong Jin Park iD, Yun-Suhk Suh iD, Oh Jeong iD, Sang-Yong Son iD, Mi Ran Jung iD, Young Suk Park iD, Dong-Wook Kim iD und 9 weitere

Journal of Gastric Cancer · 2025

DOI: 10.5230/jgc.2025.25.e34 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastric Cancer, 2025. Verfasst von Hyoung-Il Kim und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Surgery, Department of Surgery, Yonsei University Severance Hospital, Yonsei University College of Medicine, Seoul, Kore…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Gastrectomy, Laparoscopy, Adenocarcinoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medtronic Korea Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This trial (KLASS-12) compares the efficacy and safety of reduced-port laparoscopic gastrectomy (RPLG) versus conventional 5-port laparoscopic gastrectomy (CPLG) for early gastric cancer (EGC). MATERIALS AND METHODS: This multicenter, open-label, randomized controlled trial enrolled patients diagnosed with gastric adenocarcinoma (T1N0M0) at 15 university hospitals in Korea. Participants underwent RPLG or CPLG with at least D1+ lymph node dissection. The primary aim of this study was to verify the non-inferiority of RPLG to CPLG in terms of postoperative 30-day complications. RESULTS: From May 2022 to October 2023, 348 patients were randomly assigned to the RPLG and CPLG groups, with 174 patients in each group. After applying the exclusion criteria, 164 and 166 patients from the RPLG and CPLG groups, respectively, were analyzed. Complication rates were 10.4% and 9.2% for the RPLG and CPLG groups, in the intention-to-treat (ITT) population, and 10.4% vs. 7.2% in the per-protocol (PP) population. The risk difference was 0.012 (95% confidence interval [CI], -0.051 to 0.075) in the ITT population and 0.031 (95% CI, -0.030 to 0.093) in the PP population. These findings verified the non-inferiority of RPLG to CPLG, with a 10% margin. Additionally, the pain score on postoperative day 5 was significantly lower in the RPLG group (1.6% vs. 1.8%; P=0.028). The 2 groups showed no significant differences in the lymph node yield, conversion rate, or length of hospital stay. RPLG was not an independent risk factor for complications. CONCLUSIONS: RPLG is a feasible and safe alternative for patients with EGC, and its short-term outcomes are not inferior to those of CPLG. TRIAL REGISTRATION: Clinical Research Information Service Identifier: KCT0006935.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsGastrectomyLaparoscopyAdenocarcinomaHumansFemaleMaleMiddle AgedAgedPostoperative ComplicationsLymph Node ExcisionTreatment OutcomeAdultRepublic of KoreaLength of Stay

Stichwörter der Autor:innen

GastrectomyLaparoscopyMinimally invasive surgical proceduresStomach neoplasms

Autor:innen und Institutionen

  • Division of Gastrointestinal Surgery, Department of Surgery, Yonsei University Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Division of Gastrointestinal Surgery, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Division of Gastrointestinal Surgery, Department of Surgery, Ajou University School of Medicine, Suwon, Korea.
  • Division of Gastrointestinal Surgery, Department of Surgery, Korea University Ansan Hospital, College of Medicine, Korea University, Seoul, Korea.
  • Division of Gastrointestinal Surgery, Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Division of Gastrointestinal Surgery, Department of Surgery, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.

ORCID-Profile: Hyoung-Il Kim, Hoseok Seo, Hoon Hur, Chang Min Lee, Sang-Hoon Ahn, Dong Jin Park, Yun-Suhk Suh, Oh Jeong, Sang-Yong Son, Mi Ran Jung, Young Suk Park, Dong-Wook Kim, Jeong Ho Song, Yoontaek Lee, Ji-Ho Park, Shin-Hoo Park, Sejin Lee, Seong-Ho Kong, Sun-Hwi Hwang, Jong Won Kim, Han Hong Lee

Förderung

  • Medtronic Korea Ltd.

Zitieren

APA

Kim, H. I., Seo, H., Hur, H., Lee, C. M., Ahn, S. H., Park, D. J., Suh, Y. S., Jeong, O., Son, S. Y., Jung, M. R., Park, Y. S., Kim, D. W., Song, J. H., Lee, Y., Park, J. H., Park, S. H., Lee, S., Kong, S. H., Hwang, S. H., …, & Lee, H. H. (2025). Safety and Efficacy of Reduced-Port Versus Conventional Laparoscopic Distal Gastrectomy for Early Gastric Cancer: A Multicenter, Randomized, Non-inferiority Trial (KLASS-12). Journal of Gastric Cancer. https://doi.org/10.5230/jgc.2025.25.e34

Vancouver

Kim HI, Seo H, Hur H, Lee CM, Ahn SH, Park DJ, et al. Safety and Efficacy of Reduced-Port Versus Conventional Laparoscopic Distal Gastrectomy for Early Gastric Cancer: A Multicenter, Randomized, Non-inferiority Trial (KLASS-12). Journal of Gastric Cancer. 2025. doi:10.5230/jgc.2025.25.e34

BibTeX
@article{Kim2025,
  author = {Kim, Hyoung-Il and Seo, Hoseok and Hur, Hoon and Lee, Chang Min and Ahn, Sang-Hoon and Park, Dong Jin and Suh, Yun-Suhk and Jeong, Oh and Son, Sang-Yong and Jung, Mi Ran and Park, Young Suk and Kim, Dong-Wook and Song, Jeong Ho and Lee, Yoontaek and Park, Ji-Ho and Park, Shin-Hoo and Lee, Sejin and Kong, Seong-Ho and Hwang, Sun-Hwi and Kim, Jong Won and Lee, Han Hong},
  title = {Safety and Efficacy of Reduced-Port Versus Conventional Laparoscopic Distal Gastrectomy for Early Gastric Cancer: A Multicenter, Randomized, Non-inferiority Trial (KLASS-12)},
  journal = {Journal of Gastric Cancer},
  year = {2025},
  doi = {10.5230/jgc.2025.25.e34}
}
Kostenlos starten →